Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Takeda Accelerating Tie-ups in CNS Field
April 18, 2011
- Pharmacists to Participate in Dispensing Bill Review Starting in June
April 18, 2011
- Domestic Generics-only Makers to Maintain Lead in GE Drug Market: Report
April 18, 2011
- DSP, BBI Enter Strategic Partnership on Anticancer Drugs
April 18, 2011
- Regulatory Reform Shelves Online Sale of OTC Drugs, Unification of Basic Dispensing Fees
April 18, 2011
- Nippon Chemiphar Introduces MR Team System on a Full Scale
April 18, 2011
- Eisai Reorganizes Its Businesses in East Asia
April 18, 2011
- Korosho Draws Up New GL for Clinical Evaluation of Drugs for Heart Failure
April 18, 2011
- Sawai's Cetirizine OD Tab Receives Generic Drug of Year Award
April 18, 2011
- Aftershocks Disrupt Production at Some Pharma Production Facilities
April 18, 2011
- Korosho to Introduce “Yellow Letter”for Patients
April 18, 2011
- Relaxation of Restrictions on Online Sale of OTC Drugs May Enter Agenda in May: President Kodama of JPA
April 18, 2011
- Gov't to Enforce 25% Power Cuts This Summer for Major Users Including Drug Makers
April 18, 2011
- Gov't Appeals to High Court in Iressa Case
April 18, 2011
- Taisho Acquires Hoepharma of Malaysia
April 18, 2011
- Korosho Calls on Industry to Come Up with Energy Conservation Plans
April 18, 2011
- FDA Approves 1st New Treatment for Late-stage Melanoma in Over a Decade: BMS
April 18, 2011
- Eiken Licenses LAMP Technology to OptiGene
April 18, 2011
- ASKA Begins Shipments of Thyradin Substitute
April 18, 2011
- Review Period for QAB149 for COPD Extended 3 Months by FDA
April 18, 2011
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…